

ForPatients

by Roche

Alzheimer's Disease (AD)

Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02792179 BP39126

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a longitudinal, follow-up study in participants with Alzheimer's disease (AD) who previously participated in study BP29409 (NCT02187627). This study is designed to assess the longitudinal change of Tau pathology in the brain of participants with AD using the PET ligand [18F]RO6958948 and to assess the safety and tolerability of PET ligand.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02792179 BP39126
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 25 Years

Healthy Volunteers
No
